[{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/","commit":"bfc8b4e2d8","date":"2026-09-10","author":"Jude Gomila","message":"Sources: BILCAP registry and publication links; official-website source on nineteen companies","file":"src/data/companies.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.avenzotx.com\" }]"}]},{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"In-licenser of Chinese assets including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor.\"","after":"\"Avenzo in-licenses Chinese assets, including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor.\""}]}]